WO2018140411A3 - Nanoparticules polymères thérapeutiques pour une expression génique personnalisée - Google Patents

Nanoparticules polymères thérapeutiques pour une expression génique personnalisée Download PDF

Info

Publication number
WO2018140411A3
WO2018140411A3 PCT/US2018/014898 US2018014898W WO2018140411A3 WO 2018140411 A3 WO2018140411 A3 WO 2018140411A3 US 2018014898 W US2018014898 W US 2018014898W WO 2018140411 A3 WO2018140411 A3 WO 2018140411A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanoparticles
gene expression
polymeric nanoparticles
tailored
therapeutic polymeric
Prior art date
Application number
PCT/US2018/014898
Other languages
English (en)
Other versions
WO2018140411A2 (fr
Inventor
Louis Joseph BORN
John W. Harmon
Frank Lay
Guy MARTI
Christopher Ng
Zahra ALIKHASSY
Amir Ansari
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of WO2018140411A2 publication Critical patent/WO2018140411A2/fr
Publication of WO2018140411A3 publication Critical patent/WO2018140411A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Manufacturing & Machinery (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pour une administration personnalisée de polynucléotide non viral à une cellule comprenant une pluralité de nanoparticules et un polynucléotide fixé à une surface extérieure d'au moins une nanoparticule parmi la pluralité de nanoparticules et des méthodes d'utilisation et de fabrication de ladite composition. Chaque nanoparticule parmi la pluralité de nanoparticules a un polymère cationique naturel ou synthétique réticulé électrostatiquement avec un agent de réticulation électrostatique anionique. Chaque nanoparticule parmi la pluralité de nanoparticules a un potentiel zêta positif, et chaque nanoparticule parmi la pluralité de nanoparticules présente un diamètre situé dans la plage allant de 1 nm à 1 000 nm.
PCT/US2018/014898 2017-01-24 2018-01-23 Nanoparticules polymères thérapeutiques pour une expression génique personnalisée WO2018140411A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762449884P 2017-01-24 2017-01-24
US62/449,884 2017-01-24

Publications (2)

Publication Number Publication Date
WO2018140411A2 WO2018140411A2 (fr) 2018-08-02
WO2018140411A3 true WO2018140411A3 (fr) 2018-10-18

Family

ID=62978628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/014898 WO2018140411A2 (fr) 2017-01-24 2018-01-23 Nanoparticules polymères thérapeutiques pour une expression génique personnalisée

Country Status (1)

Country Link
WO (1) WO2018140411A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021081495A1 (fr) * 2019-10-25 2021-04-29 The Johns Hopkins University Nanoparticules polymères pour l'administration intracellulaire de protéines
CN114317478B (zh) * 2022-01-05 2023-10-20 北京化工大学 一种蔗糖磷酸化酶的应用及利用其制备2-α-甘油葡萄糖苷的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100086613A1 (en) * 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100086613A1 (en) * 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN, L. ET AL.: "Chitosan/beta-lactoglobulin core-shell nanoparticles as nutraceutical carriers", BIOMATERIALS, vol. 26, no. 30, October 2005 (2005-10-01), pages 6041 - 6053, XP055546989 *
CUI, Z. ET AL.: "Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 54, 2002, pages 1195 - 1203, XP055546994 *
KUMAR, A. ET AL.: "Microneedle-mediated transcutaneous immunization with plasmid DNA coated on cationic PLGA nanoparticles", JOURNAL OF CONTROLLED RELEASE, vol. 163, no. 2, October 2012 (2012-10-01), pages 230 - 239, XP055546991 *
TIYABOONCHAI, W. ET AL.: "Chitosan nanoparticles: a promising system for drug delivery", NARESUAN UNIVERSITY JOURNAL, vol. 11, no. 3, 2013, pages 51 - 66, XP055546997 *

Also Published As

Publication number Publication date
WO2018140411A2 (fr) 2018-08-02

Similar Documents

Publication Publication Date Title
EP3676244A4 (fr) Molécules présentant un groupe hydrophobe et deux groupes ioniques hydrophiles identiques et compositions correspondantes
MX2017009688A (es) Administración de partículas de agente activo hidrófobas.
WO2016172681A8 (fr) Polymères à base d'eau aptes à la chimie clic et polymères à base d'eau réticulés par chimie clic
MX2018006115A (es) Sustratos revestidos preparados con sellador a base de agua y composiciones imprimadoras.
MX2017014990A (es) Polimero de alta viscosidad con propiedades al impacto mejoradas.
EP4173615A3 (fr) Dispositifs d'administration de médicaments intravésicaux et procédés comprenant des systèmes de matrice médicament-polymère élastique
WO2017209823A3 (fr) Pâtes injectables à base de nanoparticules hybrides de phosphate de calcium et de polymère de charges opposées
WO2015143418A3 (fr) Thérapie génique pour le traitement de la rétinite pigmentaire
EP3562851A4 (fr) Dispersion aqueuse de polymere et composition aqueuse de revêtement comprenant celle-ci
WO2018140411A3 (fr) Nanoparticules polymères thérapeutiques pour une expression génique personnalisée
PH12018502646B1 (en) Material for intraocular lenses
EP3856806A4 (fr) Dispersion aqueuse de polymère et composition de revêtement aqueuse la comprenant
MX2017016941A (es) Composiciones de proteccion ultravioleta.
MX2016009338A (es) Dispersion acuosa de particulas de pigmento modificadas de forma hidrofoba.
EP3760207A4 (fr) Composition ophtalmique comprenant du diquafosol et un polymère cationique
EP3655027A4 (fr) Surfaces synthétiques de présentation d'antigènes, surfaces fonctionnalisées de manière covalente, lymphocytes t activés et leurs utilisations
MX2020012459A (es) Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
EP3409718A4 (fr) Modificateur et polymère modifié à base de diène conjugué contenant un groupe fonctionnel dérivé de celui-ci
EP3722339A4 (fr) Copolymère, composition de caoutchouc, composition de résine, pneu et produit de résine
WO2016100433A3 (fr) Compositions coiffantes comprenant des polymères de latex
MX2021004127A (es) Recubrimientos hidrofilos de polimero con lubricidad duradera.
EP3686224A4 (fr) Polymère à base d'alcool vinylique modifié, et agent de stabilisation de dispersion pour polymérisation en suspension
WO2015069384A3 (fr) Nanocomposites a base de silicone a indice de refraction eleve
EP3505546A4 (fr) Polymère d'alcool vinylique modifié, et stabilisateur de diffusion pour polymérisation en suspension
WO2017120098A8 (fr) Nanoparticules polymères stimulables, procédés de fabrication de nanoparticules polymères stimulables, et procédés d'utilisation de nanoparticules polymères stimulables

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18745361

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18745361

Country of ref document: EP

Kind code of ref document: A2